376 related articles for article (PubMed ID: 30646278)
1. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
[TBL] [Abstract][Full Text] [Related]
2. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis.
Haas JW; Bender FL; Ballou S; Kelley JM; Wilhelm M; Miller FG; Rief W; Kaptchuk TJ
JAMA Netw Open; 2022 Jan; 5(1):e2143955. PubMed ID: 35040967
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis.
Yin X; Zhao Z; Yin Y; Shen C; Chen X; Cai Z; Wang J; Chen Z; Yin Y; Zhang B
Clin Transl Sci; 2021 May; 14(3):919-933. PubMed ID: 33382906
[TBL] [Abstract][Full Text] [Related]
4. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials.
Mahr A; Golmard C; Pham E; Iordache L; Deville L; Faure P
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):731-741. PubMed ID: 28176407
[TBL] [Abstract][Full Text] [Related]
5. Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review.
Enrico D; Waisberg F; Burton J; Mandó P; Chacón M
Crit Rev Oncol Hematol; 2021 Apr; 160():103296. PubMed ID: 33675904
[TBL] [Abstract][Full Text] [Related]
6. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
7. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
Stridh A; Pontén M; Arver S; Kirsch I; Abé C; Jensen KB
JAMA Netw Open; 2020 Mar; 3(3):e201423. PubMed ID: 32196105
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
[TBL] [Abstract][Full Text] [Related]
9. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Honvo G; Reginster JY; Rabenda V; Geerinck A; Mkinsi O; Charles A; Rizzoli R; Cooper C; Avouac B; Bruyère O
Drugs Aging; 2019 Apr; 36(Suppl 1):65-99. PubMed ID: 31073924
[TBL] [Abstract][Full Text] [Related]
10. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.
Magee DE; Hird AE; Klaassen Z; Sridhar SS; Nam RK; Wallis CJD; Kulkarni GS
Ann Oncol; 2020 Jan; 31(1):50-60. PubMed ID: 31912796
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
12. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Honvo G; Reginster JY; Rannou F; Rygaert X; Geerinck A; Rabenda V; McAlindon T; Charles A; Fuggle N; Cooper C; Curtis E; Arden N; Avouac B; Bruyère O
Drugs Aging; 2019 Apr; 36(Suppl 1):101-127. PubMed ID: 31073925
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
15. Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
Curtis E; Fuggle N; Shaw S; Spooner L; Ntani G; Parsons C; Corp N; Honvo G; Baird J; Maggi S; Dennison E; Bruyère O; Reginster JY; Cooper C
Drugs Aging; 2019 Apr; 36(Suppl 1):25-44. PubMed ID: 31073922
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics for induction and maintenance of remission in Crohn's disease.
Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
[TBL] [Abstract][Full Text] [Related]
17. Probiotics for the prevention of pediatric antibiotic-associated diarrhea.
Goldenberg JZ; Lytvyn L; Steurich J; Parkin P; Mahant S; Johnston BC
Cochrane Database Syst Rev; 2015 Dec; (12):CD004827. PubMed ID: 26695080
[TBL] [Abstract][Full Text] [Related]
18. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea.
Hayes SR; Vargas AJ
Explore (NY); 2016; 12(6):463-466. PubMed ID: 27688016
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
